A new biostatistical modeling approach has the potential to support health decisions by pinpointing where HIV is concentrated ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to case presentations ...

Lucknow: Nearly six in 10 people diagnosed with HIV are reaching hospitals only after the infection has weakened their immune ...

The difference between regimens met the trial's noninferiority threshold ...

For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced ...

HYPERTENSION among adults receiving highly active antiretroviral therapy (HAART) was highly prevalent, affecting 47.4% of participants in a cross-sectional study conducted across three referral ...

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, ...

An experimental combination pill containing islatravir and ulonivirine shows promise as a weekly oral treatment option, ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced today that it will make three presentations at AIDS 2026, which is being held July 26 – 31, 2026 in Rio ...

Researchers evaluated the impact of specific antiretroviral therapy regimens on morning serum cortisol levels among people living with HIV.

A once-weekly HIV pill combining the antiretroviral drugs islatravir and lenacapavir is as effective as a widely used ...